Project description:This study investigates the transcriptional changes in murine colon adenocarcinoma MC38 cells in response to treatment with T26, a novel compound designed to modulate glutamine metabolism and immune-related pathways. RNA sequencing (RNA-Seq) was performed to compare the transcriptomic profiles of MC38 cells treated with T26 versus untreated controls. Differentially expressed genes were analyzed to elucidate the molecular mechanisms underlying T26-mediated anti-tumor activity. This dataset provides a resource for understanding how T26 impacts tumor cell-intrinsic gene expression and may inform its potential role in cancer immunotherapy.
